PRQR

Peers: KRRO WVE ADRX SLN PRME STOK BEAM ARWR IONS MIRM

Index	-
Market Cap	185.58M
Enterprise Value	66.75M
Income	-49.05M
Sales	21.39M
Book/sh	0.64
Cash/sh	0.95
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Sep 18, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	8.68
P/B	2.04
P/C	1.39
P/FCF	-
EV/EBITDA	-
EV/Sales	3.12
Quick Ratio	3.49
Current Ratio	3.49
Debt/Eq	0.17
LT Debt/Eq	0.11
Option/Short	Yes / Yes

EPS (ttm)	-0.46
EPS next Y	-0.55
EPS next Q	-0.11
EPS this Y	-5.70%
EPS next Y	-16.25%
EPS next 5Y	11.38%
EPS past 3/5Y	21.80% 15.68%
Sales past 3/5Y	68.13% -
EPS Y/Y TTM	-4.53%
Sales Y/Y TTM	19.49%
EPS Q/Q	29.54%
Sales Q/Q	135.40%
Earnings	Aug 13 BMO
EPS/Sales Surpr.	28.97% 122.24%

Insider Own	28.85%
Insider Trans	2.00%
Inst Own	51.68%
Inst Trans	20.57%
ROA	-31.23%
ROE	-57.88%
ROIC	-48.66%
Gross Margin	85.00%
Oper. Margin	-234.12%
Profit Margin	-229.34%
SMA20	-3.33%
SMA50	-18.88%
SMA200	-21.75%
Trades

Shs Outstand	141.12M
Shs Float	100.41M
Short Float	2.90%
Short Ratio	3.53
Short Interest	2.91M
52W High	2.48 -47.08%
52W Low	1.20 9.58%
Volatility	5.65% 7.35%
ATR (14)	0.09
RSI (14)	39.88
Beta	0.27
Rel Volume	0.24
Avg Volume	823.69K
Volume	171,627

Perf Week	-4.01%
Perf Month	-18.83%
Perf Quarter	-29.30%
Perf Half Y	-17.81%
Perf YTD	-34.90%
Perf Year	-39.12%
Perf 3Y	-3.31%
Perf 5Y	-83.56%
Perf 10Y	-72.02%
Recom	1.00
Target Price	8.46
Prev Close	1.38
Price	1.32
Change %	-4.71%

Consensus

Strong Buy

Avg. Price Target

$8.46

Implied Upside

+543.3%

Analysts10incl. previous ratings

Rating Distribution9 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 20, 2026	Initiated	BBofA Securities	Buy	$8	+508.4%
Mar 12, 2026	Resumed	OOppenheimer	Outperform	$9	+584.4%
Apr 29, 2025	Resumed	CCantor Fitzgerald	Overweight	$8	+508.4%
Apr 29, 2025	Initiated	EEvercore ISI	Outperform	$5	+280.2%
Mar 10, 2025	Upgrade	CCitigroup	Neutral → Buy	$4	+204.2%
Jan 10, 2025	Initiated	OOppenheimer	Outperform	$15	+1,040.7%
Oct 29, 2024	Upgrade	RRaymond James	Outperform → Strong Buy	$6 → $14	+964.6%
Nov 08, 2023	Upgrade	CChardan Capital Markets	Neutral → Buy	$2	+52.1%
Mar 30, 2023	Upgrade	JJMP Securities	Mkt Perform → Mkt Outperform	$1.50 → $5	+280.2%
Dec 22, 2022	Upgrade	CCantor Fitzgerald	Neutral → Overweight	$0.80 → $5	+280.2%
Feb 14, 2022	Downgrade	CCitigroup	Buy → Neutral	$37 → $1.70	+29.3%
Feb 11, 2022	Downgrade	SStifel	Buy → Hold	$20 → $3	+128.1%
Feb 11, 2022	Downgrade	RRaymond James	Strong Buy → Mkt Perform
Feb 01, 2022	Initiated	RRaymond James	Strong Buy	$19	+1,344.9%
May 03, 2021	Initiated	SStifel	Buy	$20	+1,420.9%
Mar 25, 2021	Reiterated	CCitigroup	Buy	$33 → $44	+3,246.0%
Nov 03, 2020	Resumed	CCantor Fitzgerald	Overweight	$22	+1,573.0%
Mar 12, 2019	Reiterated	CChardan Capital Markets	Buy	$21 → $25	+1,801.1%
Dec 19, 2018	Initiated	RRBC Capital Mkts	Outperform
Nov 15, 2018	Initiated	CCitigroup	Buy	$32	+2,333.5%

Oct-28-26 08:00AM	ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences (GlobeNewswire) +5.22%
Sep-23-26 08:00AM	ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor (GlobeNewswire) -10.53%
Sep-09-26 08:00AM	ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026 (GlobeNewswire)
Sep-02-26 08:00AM	ProQR to Participate in Upcoming Investor Conferences in September 2026 (GlobeNewswire)
Aug-14-26 12:46PM	ProQR: Q2 Earnings Snapshot (Associated Press)
07:00AM	Loading…
Aug-13-26 07:00AM	ProQR Announces Second Quarter 2026 Operating and Financial Results (GlobeNewswire)
Jun-25-26 06:35AM	ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -13.54%
06:25AM	ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform (GlobeNewswire)
May-12-26 07:00AM	ProQR Announces First Quarter 2026 Operating and Financial Results (GlobeNewswire)
May-11-26 08:00AM	ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer RNA Editing Platform (GlobeNewswire)
May-04-26 08:00AM	ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026 (GlobeNewswire) +5.81%
Apr-30-26 08:00AM	ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors (GlobeNewswire)
Apr-08-26 04:00PM	ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event (GlobeNewswire) +7.65% +8.20%
08:00AM	ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board (GlobeNewswire)
Mar-25-26 08:00AM	ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026 (GlobeNewswire) +6.04%
09:18AM	Loading…
Mar-12-26 09:18AM	ProQR: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	ProQR Announces Year End 2025 Operating and Financial Results (GlobeNewswire)
Mar-10-26 08:30AM	Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Mar-03-26 04:30PM	ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference (GlobeNewswire) -5.06% +13.33%
Feb-26-26 06:45PM	Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates (Zacks)
Feb-09-26 08:00AM	ProQR Announces Planned Changes to Board Composition (GlobeNewswire)
Jan-08-26 08:00AM	ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook (GlobeNewswire)
Dec-01-25 08:00AM	ProQR to Participate in 8th Annual Evercore Healthcare Conference (GlobeNewswire) -9.40%
Nov-06-25 08:10AM	ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -7.14%
07:08AM	ProQR: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	ProQR Announces Third Quarter 2025 Operating and Financial Results (GlobeNewswire)
Oct-28-25 08:20AM	Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Oct-20-25 08:00AM	ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025 (GlobeNewswire) +9.71%
Oct-13-25 08:30AM	ProQR to Participate in Upcoming Investor Conferences in October 2025 (GlobeNewswire)
Aug-08-25 02:02PM	ProQR: Q2 Earnings Snapshot (Associated Press Finance) +5.85%
08:40AM	Loading…
Aug-07-25 08:40AM	Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:00AM	ProQR Announces Second Quarter 2025 Operating and Financial Results (GlobeNewswire)
Jul-28-25 08:00AM	ProQR Announces Upcoming Presentation at RNA Editing Summit (GlobeNewswire)
Jun-26-25 04:30PM	ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP (GlobeNewswire) -5.56%
May-12-25 08:00AM	ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences (GlobeNewswire)
May-08-25 07:00AM	ProQR Announces First Quarter 2025 Operating and Financial Results (GlobeNewswire)
May-07-25 07:40AM	Techne (TECH) Q3 Earnings and Revenues Beat Estimates (Zacks)
May-02-25 08:00AM	ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference (GlobeNewswire) +15.70%
May-01-25 08:00AM	ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025 (GlobeNewswire)
Apr-29-25 04:31PM	ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald (TipRanks) +5.84%
04:05PM	ProQR Therapeutics initiated with an Outperform at Evercore ISI (TipRanks)
Apr-15-25 09:01AM	Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength? (Zacks)
Apr-14-25 07:00AM	ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth (GlobeNewswire) +5.36%
Mar-13-25 07:00AM	ProQR Announces Year End 2024 Operating and Financial Results (GlobeNewswire) -5.95%
Dec-12-24 07:16AM	ProQR Therapeutics announces $8.1M in new funding from RSRT (TipRanks)
Dec-11-24 07:00AM	ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration (GlobeNewswire)
Dec-10-24 08:00AM	ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist (GlobeNewswire)
Dec-06-24 06:47AM	ProQR Therapeutics price target raised to $8 from $5 at JMP Securities (TipRanks)
Dec-05-24 08:00AM	ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024 (GlobeNewswire)
Nov-08-24 07:26AM	ProQR Therapeutics sees cash runway into mid-2027 (TipRanks) +5.60%
Nov-07-24 07:00AM	ProQR Announces Third Quarter 2024 Operating and Financial Results (GlobeNewswire)
Oct-25-24 04:45PM	ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement (GlobeNewswire)
Oct-22-24 10:15PM	ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement (GlobeNewswire) -6.67% -7.67%
04:01PM	ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares (GlobeNewswire)
Oct-07-24 08:00AM	ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society (GlobeNewswire)
Sep-10-24 04:30PM	ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-08-24 07:00AM	ProQR Announces Second Quarter 2024 Operating and Financial Results (GlobeNewswire) +12.30%
Jun-18-24 08:00AM	ProQR Announces Presentation on its Axiomer RNA Editing Technology at RNA Editing Summit (GlobeNewswire)
May-09-24 07:00AM	ProQR Announces First Quarter 2024 Operating and Financial Results (GlobeNewswire)
May-08-24 08:00AM	ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer RNA Editing Program Targeting NTCP for Cholestatic Diseases (GlobeNewswire)
Apr-23-24 07:00AM	ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024 (GlobeNewswire)
Apr-22-24 04:31PM	ProQR Highlights Upcoming Presentations on Axiomer RNA Editing at ASGCT 27th Annual Meeting (GlobeNewswire)
Apr-19-24 07:00AM	ProQR Achieves Successful Defense of New Challenge to its Axiomer IP Portfolio (GlobeNewswire) +6.99%
Mar-13-24 07:00AM	ProQR Announces Year End 2023 Operating and Financial Results (GlobeNewswire) +13.66%
Feb-15-24 07:00AM	ProQR Announces Japanese Axiomer Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing (GlobeNewswire)
Jan-19-24 07:00AM	ProQR Highlights New Platform Data from Presentation on Axiomer RNA Editing Technology at Deaminet 2024 (GlobeNewswire)
Jan-05-24 07:00AM	ProQR and Rett Syndrome Research Trust Join Forces with Axiomer RNA Editing Collaboration (GlobeNewswire)
Dec-28-23 08:44AM	Is ProQR (PRQR) Stock a Solid Choice Right Now? (Zacks)
Dec-08-23 07:30AM	ProQR Therapeutics Announces Transaction Completed for Th a to Acquire Sepofarsen and Ultevursen Ophthalmic Assets (GlobeNewswire)
Nov-07-23 07:00AM	ProQR Announces Third Quarter 2023 Operating and Financial Results (GlobeNewswire) +10.66%
Nov-06-23 07:00AM	ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing (GlobeNewswire)
Sep-28-23 08:00AM	ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-27-23 07:00AM	ProQR Therapeutics Provides Update on Ophthalmic Assets (GlobeNewswire)
Sep-07-23 08:00AM	ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-08-23 06:37AM	ProQR Therapeutics N.V.'s (NASDAQ:PRQR) top owners are retail investors with 50% stake, while 31% is held by institutions (Simply Wall St.)
Aug-03-23 07:00AM	ProQR Announces Second Quarter 2023 Operating and Financial Results (GlobeNewswire)
Aug-01-23 07:00AM	ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQRs Sepofarsen and Ultevursen Ophthalmic Assets (GlobeNewswire) +7.33%
Jul-06-23 07:00AM	ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit (GlobeNewswire)
Jun-28-23 06:02AM	ProQR Therapeutics' (NASDAQ:PRQR) investors will be pleased with their impressive 109% return over the last year (Simply Wall St.)
May-18-23 07:02AM	ProQR Therapeutics N.V. (NASDAQ:PRQR) Could Be Less Than A Year Away From Profitability (Simply Wall St.)
May-16-23 07:00AM	ProQR Announces First Quarter 2023 Operating and Financial Results (GlobeNewswire) -7.29%
May-09-23 08:00AM	ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023 (GlobeNewswire)
Apr-20-23 08:00AM	ProQR Announces Upcoming Investor Conferences in April and May (GlobeNewswire)
Apr-18-23 08:00AM	ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023 (GlobeNewswire) -6.47%
Mar-29-23 12:30PM	Why Shares of ProQR Therapeutics Dropped on Wednesday (Motley Fool) -29.61%
08:00AM	ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event (GlobeNewswire)
Mar-14-23 08:00AM	ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing (GlobeNewswire) +7.85%
Mar-07-23 08:00AM	ProQR to Present at Upcoming Scientific and Industry Conferences (GlobeNewswire)
Feb-28-23 08:00AM	ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023 (GlobeNewswire)
Feb-01-23 05:11AM	Individual investors account for 45% of ProQR Therapeutics N.V.'s (NASDAQ:PRQR) ownership, while institutions account for 35% (Simply Wall St.)
Dec-29-22 11:36AM	Biotech Stock Roundup: GILD's HIV Drug Approval, PRQR Surges on LLY Deal & More (Zacks) +10.13%
Dec-23-22 12:14PM	ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly (Zacks)
Dec-22-22 09:12AM	ProQR's stock jumps on expanded RNA deal with Lilly (MarketWatch) +63.64%
08:53AM	ProQR Therapeutics Shares Soar As Eli Lilly Expands RNA Collaboration (Benzinga)
06:15AM	ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform (GlobeNewswire)
06:00AM	Lilly and ProQR to Expand RNA Editing Collaboration (PR Newswire)
05:28AM	ProQR Therapeutics (NASDAQ:PRQR) shareholders have endured a 83% loss from investing in the stock three years ago (Simply Wall St.)
Nov-14-22 04:30PM	ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 (GlobeNewswire) +5.18%
Nov-11-22 05:54AM	ProQR Therapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Nov-09-22 08:25AM	ProQR (PRQR) Reports Q3 Loss, Lags Revenue Estimates (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
de Boer Daniel Anton	Chief Executive Officer	Jul 31 '26	Buy	1.77	200,000	353,960	500,000	Aug 03 04:01 PM
Filius Bart	Director	Jul 17 '26	Buy	1.72	150,000	257,925	300,000	Jul 21 08:00 AM
de Boer Daniel Anton	Chief Executive Officer	Jul 09 '26	Buy	1.74	150,000	261,000	300,000	Jul 13 08:00 AM
de Boer Daniel Anton	Chief Executive Officer	Jul 07 '26	Buy	1.59	150,000	238,500	150,000	Jul 08 02:55 PM
Filius Bart	Director	Jun 26 '26	Buy	1.54	150,000	231,000	150,000	Jun 30 04:01 PM

ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012, and is headquartered in Leiden, the Netherlands.

FounderMr. Daniel Anton de Boer

Co-FounderDr. Gerard Platenburg Ph.D.

Chief Financial OfficerMr. Dennis Hom

Chief People & Operations OfficerMs. Sheila Sponselee

Vice President of Investor Relations & Corporate CommunicationsMs. Sarah Cue Kiely

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ProQR Therapeutics N.V

Upgrade your Finviz experience